Amgen Inc. ($AMGN) Stock Forecast: Up 5.1% Today

What is Amgen Inc.?

Amgen (NASDAQ: AMGN) is a leading biotechnology company recognized for its innovative therapies across various disease areas, such as oncology and cardiovascular diseases. The company boasts a robust product pipeline and a proven track record in the healthcare industry.

Why is Amgen Inc. going up?

AMGN stock is up 5.1% on Aug 8, 2024 18:20

• Despite a revised guidance announcement, Amgen experienced a strong bullish trend in stock performance today, demonstrating resilience within the market.
• Investor negativity toward Amgen's options trading did not significantly impact the overall positive market sentiment toward the company.
• The second-quarter results, which displayed a mix of outcomes, brought attention to the potential of Amgen's obesity medication, potentially contributing to the stock's bullish movement.
• Eli Lilly's stock upsurge, driven by surpassing analyst expectations and raising guidance in the diabetes drug sector, likely had a favorable impact on the sentiment toward biotech firms like Amgen, contributing to the bullish trend.

AMGN Price Chart

AMGN News

Amgen Options Trading: A Deep Dive into Market Sentiment - Amgen ( NASDAQ:AMGN )

Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

https://www.benzinga.com/insights/options/24/08/40256662/amgen-options-trading-a-deep-dive-into-market-sentiment

LLY Stock Alert: Why Are Eli Lilly Shares Surging Today?

Eli Lilly (NYSE: LLY ) stock rose 13% overnight after it beat analyst estimates and raised guidance. The company’s GLP-1 drugs for diabetes and weight loss, Zepbound and Mounjaro, propelled the results. The company reported net income of $2.97 billion, $3.28 per share fully diluted, on revenue of $11.3 billion . Lilly also raised its full-year revenue guidance to $45.4 billion-$46.6 billion and earnings per share guidance to $15.10-$15.40 per share . The market responded as if Lilly was selling artificial intelligence (AI) chips. Shares jumped over 13% overnight. Before the market opened, they were trading at over $874, and the market capitalization rose to over $825 billion. The Diabetes Gold Rush Lilly could predict future success after the Food and Drug Administration (FDA) announced that the drugmaker has resolved its two-year-long shortages of diabetes drugs. By the end of the first quarter, the company had seven sites producing the drugs. Despite shortages, Mounjaro had sales of $3.1 billion in the second quarter and Zepbound over $1.2 billion.

https://investorplace.com/2024/08/lly-stock-alert-why-are-eli-lilly-shares-surging-today/

Amgen Stock Slides on Lowered Guidance

Amgen shares fell 5% Wednesday after the drug developer lowered its full-year earnings guidance.

https://www.investopedia.com/amgen-stock-slides-on-lowered-guidance-8692000

Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts - Amgen ( NASDAQ:AMGN )

On Tuesday, Amgen Inc. AMGN reported mixed second-quarter results. BMO Capital Markets writes, "A commercially in-line quarter for Amgen underscores the importance of upcoming clinical readouts in obesity and inflammatory disease." The analyst keeps the Outperform rating with a price target of $362.

https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40229568/amgens-mixed-q2-results-highlight-obesity-drug-potential-analysts-focus-shifts-to-u

Amgen, Airbnb fall; Fortinet, Dynatrace rise, Wednesday, 8/7/2024

Stocks that traded heavily or had substantial price changes on Wednesday: Amgen, Airbnb fall; Fortinet, Dynatrace rise

https://abcnews.go.com/Business/wireStory/amgen-airbnb-fall-fortinet-dynatrace-rise-wednesday-872024-112646086

Trending Today

Toncoin ($TON) Crypto Forecast: Up 5.3% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.1% Today

Binance Coin ($BNB) Crypto Forecast: Up 5.1% Today

Cloudflare Inc. ($NET) Stock Forecast: Up 5.4% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Up 5.2% Today

ZCash ($ZEC) Crypto Forecast: Up 8.6% Today

Duolingo Inc. ($DUOL) Stock Forecast: Up 6.3% Today

Marvell Technology Group Ltd. ($MRVL) Stock Forecast: Up 5.1% Today

Decentraland ($MANA) Crypto Forecast: Up 8.5% Today

Sirius XM Holdings Inc. ($SIRI) Stock Forecast: Up 5.5% Today

Amgen Inc. Price History

08.01.2024 - AMGN Stock was down 6.3%

• Amgen stock experienced its worst day in over 2-1/2 years, with a significant bearish movement.
• Analysts are debating the weight loss prospects of Amgen, which could be a factor contributing to the stock's decline.
• The stock traded at a lower price compared to the previous day, indicating a downward trend.
• Despite reporting robust growth and pipeline progress in its earnings call, Amgen's stock still faced a bearish market movement.

07.01.2024 - AMGN Stock was down 6.0%

• Amgen reported Q4 earnings and revenues that exceeded expectations, indicating positive performance.
• Despite the positive earnings report, Amgen experienced a decline in sales for one of its top-selling drugs, which may have contributed to the bearish movement.
• The overall market sentiment was mixed, with major US stock indices making a comeback after being down earlier in the day. This volatility could have influenced Amgen's bearish movement.
• The AI system's assessment of higher-growth blue chips and consistent picks may not have included Amgen, leading to a negative impact on the stock.

08.01.2024 - AMGN Stock was down 6.3%

• The price target for AMGN was increased by analysts at Royal Bank of Canada, indicating positive sentiment towards the stock. However, this did not prevent the bearish movement.
• Analysts are debating the weight loss prospects of Amgen, which could be a factor contributing to the negative market movement.
• AMGN traded at a lower price compared to its previous day's close, suggesting a decline in investor confidence.
• The company's fourth-quarter adjusted net profit beat expectations, but higher operating expenses may have influenced the bearish market movement.

07.01.2024 - AMGN Stock was down 5.2%

• Amgen reported strong fourth-quarter earnings, with adjusted net profit beating expectations and total revenues increasing by 20%. This positive news should have had a bullish impact on the stock.
• However, despite the positive earnings report, Amgen's stock experienced a strong bearish movement. This could be due to profit-taking by investors who were expecting even better results or concerns about the company's future growth prospects.
• The news articles do not provide a clear reason for the bearish movement, but it is possible that other factors such as market sentiment or broader industry trends influenced the stock's decline.

07.01.2024 - AMGN Stock was down 5.5%

• The bearish movement in AMGN today can be attributed to the following factors:
• 1. Despite reporting robust growth and pipeline progress in its earnings call, the market may have reacted negatively to the decline in sales of one of Amgen's top-selling drugs, Enbrel. This could have raised concerns about the company's future revenue potential.
• 2. The market may have also been disappointed by the relatively small impact of Horizon's products on Amgen's sales in the quarter. Although the products contributed $954 million in sales, it might not have met the high expectations of investors.
• 3. The overall volatility in the biotechnology sector could have influenced the bearish movement in AMGN, as investors remain cautious and sensitive to any negative news or uncertainties surrounding the industry.
• 4. It is worth noting that despite the bearish movement, Amgen's quarterly results still exceeded analyst expectations, indicating the company's overall strength and resilience in the market. However, the decline in Enbrel sales and the market's reaction to it might have overshadowed the positive aspects of the earnings report.

03.04.2024 - AMGN Stock was up 12.6%

• Amgen's stock surged by 14% after the CEO expressed optimism about the early results from a study of the company's experimental obesity drug, MariTide.
• UBS raising Amgen's stock price target on positive MariTide comments further fueled investor confidence in the company's potential.
• The overall positive sentiment in the market, with Wall Street poised for upward momentum on the jobs report and Apple's strong performance, likely contributed to the bullish movement in Amgen's stock.
• The market's anticipation of potential interest rate cuts also added to the optimism, driving investors towards stocks like Amgen that show promise in their pipeline developments.

07.01.2024 - AMGN Stock was down 6.3%

• The bearish movement in AMGN today could be attributed to a combination of factors:
• 1. Disappointing earnings: Despite beating fourth-quarter estimates for earnings and sales, there may have been concerns among investors about the company's future growth prospects. This could have led to a sell-off in the stock.
• 2. Increased operating expenses: The news article mentions that Amgen's adjusted net profit increased 15% in the fourth quarter, but higher operating expenses may have raised concerns about the company's profitability.
• 3. Overall market sentiment: The broader market for biotechnology stocks may have influenced the bearish movement in AMGN today. If there was a general negative sentiment towards the sector, it could have weighed down on the stock's performance.
• 4. Technical factors: The stock's previous close being higher than the current trading price and the downward move of -3.79% on the previous day's price could have triggered selling pressure among traders and investors.
• Overall, the bearish movement in AMGN today could be a result of a combination of company-specific factors, market sentiment, and technical factors.

03.04.2024 - AMGN Stock was up 12.9%

• Amgen's shares surged following positive updates on its GLP-1 drug and the MariTide trial outlook, leading to upgrades by William Blair and Barclays.
• The announcement of "very encouraging" clinical trial results for Amgen's new injectable weight-loss drug, MariTide, sparked investor optimism and drove the stock price higher.
• With the weight-loss drug market projected to exceed $80 billion in annual sales by 2030, Amgen's MariTide is positioned to compete with other blockbuster drugs, such as Zepbound and Wegovy, further boosting investor confidence in the company's growth prospects.
• CEO Robert Bradway's reassurance of MariTide's differentiated profile and addressing unmet medical needs, coupled with plans for upcoming trial phases, has instilled faith in the drug's potential success and contributed to the bullish movement in Amgen's stock.

07.07.2024 - AMGN Stock was down 5.0%

• Strong second-quarter sales were reported by Amgen, surpassing consensus estimates and showing a 20% year-over-year growth in sales.
• Despite the positive earnings and sales beat, the stock price fell, indicating that investors may have had higher expectations for the company.
• Concerns were raised among investors about the company's future growth prospects due to the tightening of revenue and earnings guidance for 2024.
• The mixed reaction to Amgen's earnings report and outlook suggests that while the company faces near-term challenges, its long-term growth prospects remain strong, as indicated by analysts.

02.07.2024 - AMGN Stock was down 2.2%

• Amgen's stock price might have experienced a bearish movement due to profit-taking by investors after a recent positive uptrend.
• The upcoming announcement of the second quarter financial results could have created uncertainty among investors, leading to a sell-off.
• Analyst estimates for Amgen's Q2 earnings might have fallen short of expectations, causing a negative sentiment in the market.
• Despite the bearish movement, the long-term growth prospects of Amgen and the biotechnology sector remain promising, driven by factors such as government support, regulatory advancements, and the demand for advanced therapeutics.

07.07.2024 - AMGN Stock was down 7.4%

• Amgen disclosed a mix of results in the second quarter, with earnings coming in below the expectations of analysts, resulting in a bearish market response.
• Analysts are placing emphasis on the imminent clinical updates in the areas of obesity and inflammatory disease, underscoring the pivotal role of forthcoming advancements for the company's expansion prospects.
• Despite exceeding the second-quarter predictions for earnings and sales, the stock witnessed a decline, suggesting that investors possibly sought more robust guidance or performance criteria.
• The prevailing market sentiment towards Amgen appears to be cautious due to immediate hurdles, yet analysts retain a positive outlook on the company's long-term growth possibilities.

08.07.2024 - AMGN Stock was up 5.1%

• Despite a revised guidance announcement, Amgen experienced a strong bullish trend in stock performance today, demonstrating resilience within the market.
• Investor negativity toward Amgen's options trading did not significantly impact the overall positive market sentiment toward the company.
• The second-quarter results, which displayed a mix of outcomes, brought attention to the potential of Amgen's obesity medication, potentially contributing to the stock's bullish movement.
• Eli Lilly's stock upsurge, driven by surpassing analyst expectations and raising guidance in the diabetes drug sector, likely had a favorable impact on the sentiment toward biotech firms like Amgen, contributing to the bullish trend.